Atherosclerosis - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Atherosclerosis – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Atherosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Atherosclerosis: Overview
Plaque (fatty deposits) build up in arteries is called atherosclerosis. These deposits are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). As plaque builds up, the wall of the blood vessel thickens. This narrows the channel within the artery – reducing blood flow. Atherosclerosis is a slow, lifelong progression of changes in the blood vessels that may start in childhood and get worse faster with the age. Atherosclerosis usually doesn't cause any symptoms until blood supply to an organ is reduced. When this happens, symptoms vary, depending on the specific organ involved: Heart — Symptoms include the chest pain of angina and shortness of breath, sweating, nausea, dizziness or light-headedness, breathlessness or palpitations. Brain — When atherosclerosis narrows brain arteries, it can cause dizziness or confusion; weakness or paralysis on one side of the body. Abdomen — When atherosclerosis narrows the arteries to the intestines, there may be dull or cramping pain in the middle of the abdomen. There is no cure for atherosclerosis, but treatment can slow or halt the worsening of the disease. The major treatment goal is to prevent significant narrowing of the arteries so that symptoms never develop and vital organs are never damaged.
'Atherosclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atherosclerosis pipeline landscape is provided which includes the disease overview and Atherosclerosis treatment guidelines. The assessment part of the report embraces, in depth Atherosclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atherosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Atherosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atherosclerosis Emerging Drugs
Further product details are provided in the report
Atherosclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Atherosclerosis drugs segregated based on following parameters that define the scope of the report, such as:
Atherosclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atherosclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atherosclerosis drugs.
Atherosclerosis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Atherosclerosis – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Atherosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Atherosclerosis: Overview
Plaque (fatty deposits) build up in arteries is called atherosclerosis. These deposits are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). As plaque builds up, the wall of the blood vessel thickens. This narrows the channel within the artery – reducing blood flow. Atherosclerosis is a slow, lifelong progression of changes in the blood vessels that may start in childhood and get worse faster with the age. Atherosclerosis usually doesn't cause any symptoms until blood supply to an organ is reduced. When this happens, symptoms vary, depending on the specific organ involved: Heart — Symptoms include the chest pain of angina and shortness of breath, sweating, nausea, dizziness or light-headedness, breathlessness or palpitations. Brain — When atherosclerosis narrows brain arteries, it can cause dizziness or confusion; weakness or paralysis on one side of the body. Abdomen — When atherosclerosis narrows the arteries to the intestines, there may be dull or cramping pain in the middle of the abdomen. There is no cure for atherosclerosis, but treatment can slow or halt the worsening of the disease. The major treatment goal is to prevent significant narrowing of the arteries so that symptoms never develop and vital organs are never damaged.
'Atherosclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atherosclerosis pipeline landscape is provided which includes the disease overview and Atherosclerosis treatment guidelines. The assessment part of the report embraces, in depth Atherosclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atherosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Atherosclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Atherosclerosis.
This segment of the Atherosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atherosclerosis Emerging Drugs
- Aloricumab: Sanofi/ Regeneron
- VB 201: VBL therapeutics
Further product details are provided in the report
Atherosclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Atherosclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Atherosclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Atherosclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atherosclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atherosclerosis drugs.
Atherosclerosis Report Insights
- Atherosclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atherosclerosis drugs?
- How many Atherosclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atherosclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atherosclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atherosclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Atherosclerosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atherosclerosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atherosclerosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atherosclerosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Regsitered)
Comparative Analysis
Aloricumab: Sanofi/ Regeneron
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
VB 201: VBL therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
BT 200: Band Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Atherosclerosis Key Companies
Atherosclerosis Key Products
Atherosclerosis- Unmet Needs
Atherosclerosis- Market Drivers and Barriers
Atherosclerosis- Future Perspectives and Conclusion
Atherosclerosis Analyst Views
Atherosclerosis Key Companies
Appendix
Executive Summary
Atherosclerosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atherosclerosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atherosclerosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atherosclerosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Regsitered)
Comparative Analysis
Aloricumab: Sanofi/ Regeneron
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
VB 201: VBL therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
BT 200: Band Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Atherosclerosis Key Companies
Atherosclerosis Key Products
Atherosclerosis- Unmet Needs
Atherosclerosis- Market Drivers and Barriers
Atherosclerosis- Future Perspectives and Conclusion
Atherosclerosis Analyst Views
Atherosclerosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Atherosclerosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Atherosclerosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Atherosclerosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Atherosclerosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
